-
公开(公告)号：US09308186B2
公开(公告)日：2016-04-12
申请号：US13323510
申请日：2011-12-12
Applicant: Roshantha A. Chandraratna
Inventor： Roshantha A. Chandraratna
IPC: A61K31/192 , A61K45/06
CPC classification number: A61K31/192 , A61K31/282 , A61K31/337 , A61K45/06 , C12Q1/6886 , C12Q2600/158 , A61K2300/00
Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
Abstract translation: 公开了一种治疗癌症的方法，其包括向需要这种治疗的患者施用低于RAR活化阈值以及等于或高于RXR有效剂量的RXR激动剂。
-
公开(公告)号：US20090203720A1
公开(公告)日：2009-08-13
申请号：US11433083
申请日：2006-05-12
Applicant: Yi Zhao , Roshantha A. Chandraratna
Inventor： Yi Zhao , Roshantha A. Chandraratna
IPC: A61K31/19 , C12Q1/68 , G01N33/53 , C12N5/00 , A61K31/5513 , A61K31/192 , A61K31/4418 , A61K31/403 , A61K31/343 , A61K31/505 , A61K31/7105 , A61K31/713
CPC classification number: A61K45/06 , A61K31/00 , A61K2300/00
Abstract: Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or proliferation, such as a cancer, can be treated with inhibitors of casein kinase 1α.
Abstract translation: 通过施用RXR激动剂和酪蛋白激酶1alpha的抑制剂，细胞生长被抑制和/或在细胞中诱导细胞死亡。 可以筛选细胞或组织以增强细胞死亡或细胞生长干扰的易感性。 可以用酪蛋白激酶1α抑制剂治疗以不受控制的细胞生长或增殖为特征的疾病，例如癌症。
-
3.发明授权Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity 失效具有RARGAMMA类视黄醇受体拮抗剂活性的二取代查耳酮肟公开(公告)号：US07432388B2
公开(公告)日：2008-10-07
申请号：US11810047
申请日：2007-06-04
Applicant: Kwok Yin Tsang , Santosh Sinha , Xiaoxia Liu , Smita Bhat , Roshantha A. Chandraratna
Inventor： Kwok Yin Tsang , Santosh Sinha , Xiaoxia Liu , Smita Bhat , Roshantha A. Chandraratna
IPC: C07C205/00 , C07C229/00 , C07C249/00
CPC classification number: C07D335/06 , C07C251/48 , C07C2602/08 , C07C2602/10 , C07D215/12
Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RARγretinoid receptors.
Abstract translation: 变量具有本说明书中描述的值的式的化合物是RAR类视黄醇受体的拮抗剂。
-
4.发明授权5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity 失效具有血清葡萄糖还原活性的5,6,7,8-四氢萘-2-基2,6-二氟庚酸公开(公告)号：US06759547B1
公开(公告)日：2004-07-06
申请号：US10341837
申请日：2003-01-14
Applicant: Richard L. Beard , Haiqing Yuan , Yang-Dar Yuan , Roshantha A. Chandraratna
Inventor： Richard L. Beard , Haiqing Yuan , Yang-Dar Yuan , Roshantha A. Chandraratna
IPC: C07C6976
CPC classification number: C07C59/72 , C07C69/734 , C07C2602/10
Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
Abstract translation: 所述变体具有本说明书中定义的含义的化合物能够降低糖尿病哺乳动物的血清葡萄糖水平，而没有降低血清甲状腺素水平的不良副作用。
-
公开(公告)号：US06713647B2
公开(公告)日：2004-03-30
申请号：US10364225
申请日：2003-02-11
Applicant: Jayasree Vasudevan , Alan T. Johnson , Liming Wang , Roshantha A. Chandraratna
Inventor： Jayasree Vasudevan , Alan T. Johnson , Liming Wang , Roshantha A. Chandraratna
IPC: C07C22946
Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids.
Abstract translation: 具有式4的化合物，其中符号具有本说明书中定义的含义是细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并且用于治疗响应于类视黄醇治疗的疾病。
-
Patent Agency Ranking
6.发明授权1-imidazolyl substituted tetrahydronaphthalene derivatives as inhibitors of eytochrome P450RAI 失效1-咪唑基取代的四氢萘衍生物作为眼睛色素P450RAI的抑制剂公开(公告)号：US06603019B2
公开(公告)日：2003-08-05
申请号：US10079993
申请日：2002-02-21
Applicant: Jayasree Vasudevan , Alan T. Johnson , Liming Wang , Roshantha A. Chandraratna
Inventor： Jayasree Vasudevan , Alan T. Johnson , Liming Wang , Roshantha A. Chandraratna
IPC: C07D23364
Abstract: Compounds having Formula 4 wherein the symbols have the meaning defined in the specification are inhibitors of the cytochrome P450RAI (retinoic acid inducible) enzyme, and are used for treating diseases responsive to treatment by retinoids
Abstract translation: 具有式4的化合物，其中符号具有本说明书中定义的含义是细胞色素P450RAI（视黄酸诱导型）酶的抑制剂，并且用于治疗响应于类视黄醇治疗的疾病
-
![ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO [1,2-G]CHROM-3-ENE, BENZO[1,2-G]-THIOCHROM-3-ENE AND BENZO [1,2-G]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY](/abs-image/US/2003/03/25/US06538149B1/abs.jpg.150x150.jpg)
7.发明授权ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO [1,2-G]CHROM-3-ENE, BENZO[1,2-G]-THIOCHROM-3-ENE AND BENZO [1,2-G]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY 失效芳基或杂芳基取代的3,4-二羟基乙腈和芳基或取代的苄基[1,2-G] CH 3 -3-烯，苯并[1,2-G] - 噻唑酮-3-烯和苯并[1,2-G ] -1,2-二氢喹啉衍生物具有抗原拮抗剂或反义抗体激动剂类型生物活性公开(公告)号：US06538149B1
公开(公告)日：2003-03-25
申请号：US09482700
申请日：2000-01-13
Applicant: Vidyasagar Vuligonda , Alan T. Johnson , Roshantha A. Chandraratna
Inventor： Vidyasagar Vuligonda , Alan T. Johnson , Roshantha A. Chandraratna
IPC: C07C6974
CPC classification number: C07C69/76 , C07C45/00 , C07C47/548 , C07C2603/24 , C07D213/55 , C07D311/92 , C07D333/24 , C07D335/08 , C07D409/06
Abstract: Compounds of the formula where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.
Abstract translation: 符号具有本说明书中定义的含义的化合物具有类视黄醇，维生素A拮抗剂和/或类视黄醇反相激动剂样生物活性。
-
公开(公告)号：US06521641B1
公开(公告)日：2003-02-18
申请号：US09591253
申请日：2000-06-09
Applicant: Elliott S. Klein , Yang-Dar Yuan , Roshantha A. Chandraratna
Inventor： Elliott S. Klein , Yang-Dar Yuan , Roshantha A. Chandraratna
IPC: A61P1516
CPC classification number: A61K31/382 , A61K31/00 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/203 , A61K31/353 , A61K31/47 , A61K31/695 , Y10S514/841
Abstract: Methods and compositions for inhibiting or preventing spermatogenesis in a male mammal. Also disclosed are compounds and formulations for use in such methods.
Abstract translation: 用于抑制或预防雄性哺乳动物精子发生的方法和组合物。 还公开了用于这些方法的化合物和制剂。
-
9.发明授权1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity 失效1-烷氧基和1-酰氧基取代的环己-1-烯化合物和具有类视黄醇样生物活性的硫和1-烷氧基羰基类似物公开(公告)号：US06465646B1
公开(公告)日：2002-10-15
申请号：US09634726
申请日：2000-08-04
Applicant: Richard L. Beard , Diana F. Colon , Roshantha A. Chandraratna
Inventor： Richard L. Beard , Diana F. Colon , Roshantha A. Chandraratna
IPC: C07D23702
CPC classification number: C07C403/02 , C07C69/76 , C07C2601/16 , C07F7/081 , C07F7/0812 , C07F7/1804
Abstract: Compounds of Formula 1 and of Formula 2 where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid negative hormone like biological activity.
Abstract translation: 符号具有本说明书中定义的含义的式1和式2的化合物具有类视黄醇，维生素A拮抗剂或类视黄醇阴性激素，如生物活性。
-
10.发明授权公开(公告)号：US06452032B1
公开(公告)日：2002-09-17
申请号：US09591042
申请日：2000-06-09
Applicant: Richard L. Beard , Michael E. Garst , Roshantha A. Chandraratna
Inventor： Richard L. Beard , Michael E. Garst , Roshantha A. Chandraratna
IPC: C07F710
CPC classification number: C07F7/0807 , C07F7/081 , C07F7/0814
Abstract: Silicone-containing organic compounds useful as modulators of mammalian nuclear hormone receptors, particularly the retinoid receptors and the farnesoid receptors.
Abstract translation: 有机硅有机化合物可用作哺乳动物核激素受体的调节剂，特别是类视黄醇受体和法呢基受体。
-
-
-
-
-
-
-
-
-
Search Results
177
records
(took 0.029 seconds)
